# Is Quest Diagnostics Incorporated (DGX) overvalued?

Source: https://www.equity-rank.com/is-it-overvalued/DGX

**On Equity Rank's model estimate, DGX trades close to its fair value (8% below it).** Quest Diagnostics Incorporated (DGX) last closed at $255.63; the multi-method model fair value is $277.81.

| Price | Model fair value | Price vs model |
| --- | --- | --- |
| $255.63 | $277.81 | 8% below |

## What the answer rests on

- 5 of 12 valuation methods put DGX's value above its price and 7 put it below, so the methods disagree.
- To justify today's price, DGX's free cash flow would need to grow about 2.6% a year for ten years (a reverse discounted cash flow). Over the last three years it actually grew 1.1% a year.
- DGX trades at 25.5 times its last year's earnings, against a median of 38.3 for 26 profitable Life Sciences Tools companies.
- Over the past year the price sat below the model fair value on 100% of trading days. The gap ranged from 15% below to 0% below the model fair value.

## Read this before relying on it

The model fair value is an estimate from published financial statements. It is not a forecast of where the price goes, and it can be wrong. Within 10% either side we call it close to fair value: valuation models are not precise enough to read more into a smaller gap. Our own lists have no proven edge over the market yet; [the live record](https://www.equity-rank.com/track-record) shows every result, misses included.

Data as of Fri, Nov 6, 2026. Informational only — not investment advice.

[Every valuation method behind DGX's fair value](https://www.equity-rank.com/stocks/DGX) · [What prices assume](https://www.equity-rank.com/priced-in) · [Other companies](https://www.equity-rank.com/is-it-overvalued)

---

Fair value is a model estimate under stated assumptions — not a price target, not a prediction, and not a recommendation. This page is research information, not investment advice. Equity Rank is not a registered investment adviser.